PRAX

NEUTRALEarnings

Praxis Precision Medicines, Inc

Last Updated: 2026-02-19

Price

$331.61

+0.81%

Signal52 tracks Praxis Precision Medicines, Inc across 25+ technical signals, monitoring regime shifts, volatility patterns, and institutional flow. Our AI analyzes PRAX daily, identifying actionable setups and risk levels based on multi-timeframe confluence and market conditions.

Latest Analysis2026-02-19

PRAX Stock Analysis - 2026-02-19

PRAX is actively defying the 'Caution' macro regime by absorbing a Q4 EPS miss (-$3.50 vs -$3.09) to trade higher, a classic 'Bad News Bought' signal. The bullish thesis is anchored by the confirmation of two NDA submissions (Ulixacaltamide & Relutrigine) and a fortress balance sheet (~$1.5B cash) that de-risks operations through 2028. While the broad market frets over geopolitical war drums, PRAX is trading on idiosyncratic regulatory progress, validating the 'Rocket Ships' divergence noted by the CIO.

View this analysis on 2026-02-19 →

Key Takeaways

Technical Signals

Score: 6.2

Priority

DNA Signals

ALPHA MALESTEADY CLIMBGOLDEN CROSSPERFECT STACK

Action Signals

QUIET ACCUMULATIONSMA BOUNCE

Risk Signals

None detected.

← Back to Dashboard